Get the Stockscreener App
1.18
6.35%
-0.08
After Hours:
1.20
0.02
+1.69%
Geron Corp stock is traded at $1.18, with a volume of 15.88M.
It is down -6.35% in the last 24 hours and down -15.11% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.26
Open:
$1.265
24h Volume:
15.88M
Relative Volume:
1.06
Market Cap:
$878.94M
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-3.6875
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
-14.49%
1M Performance:
-15.11%
6M Performance:
-72.24%
1Y Performance:
-69.59%
1-Day Range:
$1.17
$1.33
1-Week Range:
$1.17
$1.46
52-Week Range:
$1.17
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.18 | 878.94M | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 3D Systems Corporation - GlobeNewswire Inc.
Geron: Rytelo's Limited Adoption And Flat Demand Signal Troubled Outlook (Rating Downgrade) - Seeking Alpha
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain Officers – GERN - GlobeNewswire Inc.
Lost Money on Geron Corporation (GERN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse
Geron (GERN) Faces Downgrade Amid Rytelo Rollout Concerns - GuruFocus
Geron slips as Scotiabank downgrades on sales challenges for blood cancer drug - MSN
Geron stock is downgraded at Scotiabank (GERN:NASDAQ) - Seeking Alpha
Geron outlines strategies to boost RYTELO adoption and anticipates Phase III myelofibrosis trial results in 2026 - MSN
Geron (GERN) Price Target Reduced by Wedbush Amid Uptake Challenges | GERN Stock News - GuruFocus
Geron Corporation (NASDAQ:GERN) Q1 2025 Earnings Call Transcript - Insider Monkey
Geron (GERN) Experiences Notable Downgrade from Scotiabank | GERN Stock News - GuruFocus
Geron (GERN) Faces Downgrade Amid Rytelo Launch Challenges | GERN Stock News - GuruFocus
Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Geron Corporation(GERN) Shareholders - PR Newswire
Geron: Q1 Earnings Snapshot - New Haven Register
Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic Growth Initiatives - GuruFocus
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Why Geron Stock Crept Higher Today - Barchart.com
Geron Corporation (GERN) Targets RYTELO Growth Amid Revenue Dip - GuruFocus
Geron Corp. Posts Narrower Loss In Q1 - Nasdaq
Earnings call transcript: Geron meets Q1 2025 EPS forecast, stock dips - Investing.com
Geron (GERN) Posts Narrower Q1 Loss Amid Revenue Surge - GuruFocus
Geron earnings matched, revenue fell short of estimates - Investing.com
Geron Corp Q1 2025 Earnings: EPS Beats Estimates at -$0.03, Revenue Misses at $39.6 Million - GuruFocus
Geron (GERN) Reports Q1 Revenue Below Expectations, Focuses on RYTELO's U.S. Potential | GERN Stock News - GuruFocus
Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights - Stock Titan
GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights - PR Newswire
Holzer & Holzer, LLC Reminds Investors of the May 12, 2025 - GlobeNewswire
Geron (GERN) Q1 Earnings Preview: Market Awaits Key Results - GuruFocus
INVESTOR DEADLINE NEXT WEEK: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGERN - PR Newswire
Kirby McInerney LLP Urges Investors in Geron Corporation (GERN) to Inquire About Their Rights in Class Action Lawsuit - Business Wire
GERN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - GlobeNewswire
Shareholders that lost money on Geron Corporation(GERN) should contact Levi & Korsinsky about pending Class Action - GlobeNewswire Inc.
Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - StreetInsider
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - PrimePublishers.com
GERN INVESTOR NOTICE: Geron Corporation Investors with Substanti - GuruFocus
Shareholders that lost money on Geron Corporation(GERN) Urged to Join Class ActionContact The Gross Law Firm to Learn More - The Malaysian Reserve
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in The Bancorp, Inc. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Geron Corporation Investors: Please contact the Portnoy Law - GlobeNewswire
Equinox Gold to Announce First Quarter Financial and Operating Results on May 7, 2025 - The Globe and Mail
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Canopy Growth Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
GERN Deadline: Rosen Law Firm Urges Geron Corporation (NASDAQ: GERN) Stockholders to Contact the Firm for Information About Their Rights - Business Wire
Levi & Korsinsky Notifies Geron Corporation Investors of a Class Action Lawsuit and Upcoming DeadlineGERN - Stockhouse
GERN INVESTOR NOTICE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - The Victoria Advocate
GERN INVESTOR NOTICE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Investors who lost money on Geron Corporation(GERN) should contact Levi & Korsinsky about pending Class ActionGERN - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
The Gross Law Firm Reminds Geron Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Geron Corporation and Certain OfficersGERN - PR Newswire
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):